Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

Michael H Davidson, Michael Szarek, Philip Scheltens, Everard Vijverberg, Andrew Hsieh, Marc Ditmarsch, Douglas Kling, Danielle Curcio, Stephen J Nicholls, Kausik K Ray, Jeffrey L. Cummings, John JP Kastelein

Open source

DOI
10.1016/j.tjpad.2025.100394
Published
2026-01
Container
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2025.100394,
  title = {Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease},
  author = {Michael H Davidson and Michael Szarek and Philip Scheltens and Everard Vijverberg and Andrew Hsieh and Marc Ditmarsch and Douglas Kling and Danielle Curcio and Stephen J Nicholls and Kausik K Ray and Jeffrey L. Cummings and John JP Kastelein},
  year = {2026},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  doi = {10.1016/j.tjpad.2025.100394},
  url = {https://doi.org/10.1016/j.tjpad.2025.100394}
}

RIS

TY  - JOUR
TI  - Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
AU  - Michael H Davidson
AU  - Michael Szarek
AU  - Philip Scheltens
AU  - Everard Vijverberg
AU  - Andrew Hsieh
AU  - Marc Ditmarsch
AU  - Douglas Kling
AU  - Danielle Curcio
AU  - Stephen J Nicholls
AU  - Kausik K Ray
AU  - Jeffrey L. Cummings
AU  - John JP Kastelein
PY  - 2026
JO  - The Journal of Prevention of Alzheimer's Disease
DO  - 10.1016/j.tjpad.2025.100394
UR  - https://doi.org/10.1016/j.tjpad.2025.100394
ER  - 

APA

Davidson, M. H., Szarek, M., Scheltens, P., Vijverberg, E., Hsieh, A., Ditmarsch, M., Kling, D., Curcio, D., Nicholls, S. J., Ray, K. K., Cummings, J. L., & Kastelein, J. J. (2026). Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2025.100394

Source records